Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 April 2019.

Powered by Capital Market - Live News

Net profit of Ajanta Pharma declined 54.63% to Rs 66.90 crore in the quarter ended December 2018 as against Rs 147.47 crore during the previous quarter ended December 2017. Sales declined 17.36% to Rs 485.11 crore in the quarter ended December 2018 as against Rs 587.05 crore during the previous quarter ended December 2017.

Powered by Capital Market - Live News

The Board of Ajanta Pharma at its meeting held on 30 January 2019 has approved the proposal to buyback of not exceeding 7,69,230 equity shares (representing 0.87% of the total number of equity shares in the paid-up share capital of the Company) at a price of Rs. 1,300 per equity share (the Buy Back Offer Price) payable in cash for an aggregate consideration not exceeding Rs. 100 crore (the Buyback Offer Size) being 5.22% of the aggregate of the fully paid up equity share capital and free reserves as per the audited standalone financial statements and 4.96% and audited consolidated financial statements of the Company for the financial year ended 31 March 2018 (the last audited financial statements available as on the date of Board meeting recommending the proposal of the Buyback).

Powered by Capital Market - Live News

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 January 2019, to consider and approve unaudited consolidated & standalone Financial Results of the Company for the third quarter ended 31st December 2018

Powered by Capital Market - Live News